Highlights Newsletter 3
This newsletter presents you the following key sessions:
4. First-line atezolizumab for patients with NSCLC not eligible for a platinum-containing regimen
This newsletter presents you the following key sessions:
4. First-line atezolizumab for patients with NSCLC not eligible for a platinum-containing regimen
Medical writer
Medical writer